June 5, 2020 / 5:32 AM / a month ago

BRIEF-Novartis Says Phase IIIb Argon Study Meets Primary Endpoint

June 5 (Reuters) - Novartis AG:

* NOVARTIS PHASE IIIB ARGON STUDY MEETS PRIMARY ENDPOINT IN A COMPARISON OF ENERZAIR® BREEZHALER® (QVM149) VERSUS A FREE COMBINATION OF TWO EXISTING INHALED TREATMENTS IN UNCONTROLLED ASTHMA Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below